The GLP-1s That Were Quietly Discontinued — and What They Tell You About the Ones Left

If you research GLP-1 medications, you will read about Byetta, Bydureon BCise, and Victoza as if you can walk into a pharmacy and fill them today. You mostly can't. These were discontinued in the United States in 2024, and the fact that so much published content still presents them as current options is a small but real hazard — it sends people asking for drugs their pharmacy can no longer order.

Here's the accurate version, and why the discontinuations are actually a useful lens on the drugs that remain.

What was discontinued, and when

• Victoza (liraglutide) — the once-daily injection — was discontinued in the U.S. in April 2024.
• Byetta (exenatide) and Bydureon BCise (extended-release exenatide) were discontinued in the U.S. in October 2024.

These weren't safety recalls. They were commercial discontinuations — the manufacturers stopped making and selling them. That distinction matters: a recalled drug is pulled because something's wrong with it; a discontinued drug is simply no longer produced, usually because newer options captured the market and the older ones stopped making business sense.

Why the older GLP-1s lost

The discontinued drugs share a trait: they were harder to take, less effective, or both, compared with what replaced them.

• Byetta was twice-daily. Victoza was once-daily. In a category where the current standard is a once-weekly injection, a drug you inject twice a day is a hard sell no matter how well it works.
• Bydureon BCise was weekly, but its extended-release formulation was fiddly to prepare and inject compared with a modern pen.
• On raw effectiveness, the older exenatide and liraglutide products produced less weight loss and less glucose lowering than semaglutide and tirzepatide. When the newer molecules arrived with better results and less frequent dosing, the older ones had no lane left.

So the discontinuations tell you something real about the survivors: the drugs still on the market — semaglutide and tirzepatide — won on the two axes that decide these things, convenience and magnitude of effect. That's the same reason the head-to-head weight-loss numbers for the current drugs are so much larger than the older ones ever posted.

If a discontinued GLP-1 is still on your chart

Two situations come up:

You're still taking one. Some patients were stable on Victoza or an exenatide product and are now working through remaining supply or a transition. If that's you, this is a prescriber conversation, not a stop-cold decision — the point is to plan a switch to a current agent, not to run out unexpectedly. Don't stop an antidiabetic medication on your own because you read it was discontinued; arrange the transition.

You're reading old advice. If an article, a forum post, or even a clinic handout is recommending Byetta or Victoza as a live option, treat the whole source as out of date. Content that hasn't been updated since early 2024 will be wrong about more than just which drugs exist — it'll be wrong about prices, shortages, and programs too. The GLP-1 landscape moved faster in 2024–2026 than almost any drug category, and undated content ages badly.

I keep a dated, regularly-checked news log of exactly these kinds of changes — discontinuations, approvals, shortage resolutions — here, specifically so that "is this still true?" has an answer with a date on it.

The one that wasn't discontinued — and why the distinction matters

Not every older GLP-1 left. Saxenda (liraglutide for weight loss) — the same molecule as Victoza but branded and dosed for obesity — is a separate product with its own status, and it's a good example of why you can't reason from molecule to availability. Victoza (liraglutide, diabetes label) being discontinued does not automatically mean the liraglutide weight-loss product shares its fate. Brand, label, and indication each have their own commercial life. If a specific product matters to you, check that exact brand, not the molecule.

You can see the current status of the individual older brands — Byetta, Victoza, and Saxenda — laid out separately for this reason.

The takeaway

Three GLP-1 brands left the U.S. market in 2024: Victoza in April, Byetta and Bydureon BCise in October. They were discontinued for commercial reasons, not safety ones, and they lost because the newer molecules were both easier to take and more effective. The practical lessons: if you're on one, plan a managed switch rather than an abrupt stop; and if a source is still recommending them in the present tense, that source is old enough that you shouldn't trust its other claims either. In this category, the date on the information is almost as important as the information.

Discontinuation dates reflect U.S. market status as of the 2024 manufacturer announcements; verified current July 2026. This is general information, not medical advice — never stop or switch a prescribed medication without your prescriber.